Thursday, May 30, 2013

Updated:Trade Call Opinion: $TSRX For a Bounce Back Over $8

Updated:Trade Call Opinion: $TSRX For a Bounce Back Over $8
at No comments:

Tuesday, May 28, 2013

BioDelivery Sciences Primed To Grab Its Share Of The $1.5 Billion Opioid Market - Seeking Alpha

BioDelivery Sciences Primed To Grab Its Share Of The $1.5 Billion Opioid Market - Seeking Alpha
at No comments:

Thursday, May 23, 2013

I bought BioDelivery Sciences (BDSI) on Bullish Chart: Solid Small Cap Spec Investment.

I bought BioDelivery Sciences (BDSI) on Bullish Chart: Solid Small Cap Spec Investment.
at No comments:

Tuesday, May 21, 2013

GTx Pharma Showing Bullish Chart Before Upcoming June Catalyst Data Release

GTx Pharma Showing Bullish Chart Before Upcoming June Catalyst Data Release
at No comments:

Wednesday, May 15, 2013

I bought Antares @ $3.95, I see a move to $4.35 short term

I bought Antares @ $3.95, I see a move to $4.35 short term
at No comments:

Tuesday, May 14, 2013

Significant Near-Term Top-Line Data Catalyst And Platform Technology Should Rally Insmed -- Trefis

Significant Near-Term Top-Line Data Catalyst And Platform Technology Should Rally Insmed -- Trefis
at No comments:

Insmed: Top-Line Data Should Rally Stock | Investing.com

Insmed: Top-Line Data Should Rally Stock | Investing.com
at No comments:

Significant Near-Term Top-Line Data Catalyst And Platform Technology Should Propel Insmed - Seeking Alpha

Significant Near-Term Top-Line Data Catalyst And Platform Technology Should Propel Insmed - Seeking Alpha
at No comments:

Tuesday, May 7, 2013

Near-Term Catalysts And High Insider Ownership Make GTx An Attractive Buy - Seeking Alpha

Near-Term Catalysts And High Insider Ownership Make GTx An Attractive Buy - Seeking Alpha
at No comments:

Monday, May 6, 2013

GTx pursues three drug studies; shares rise - Proactiveinvestors (NA)

GTx pursues three drug studies; shares rise - Proactiveinvestors (NA)
at No comments: